福安药业(300194) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 691,025,769.13, representing a year-over-year increase of 25.03% compared to CNY 552,693,027.82 in Q1 2022[5] - Net profit attributable to shareholders for Q1 2023 was CNY 86,023,255.31, a significant increase of 130.86% from CNY 37,261,834.25 in the same period last year[5] - The net profit after deducting non-recurring gains and losses was CNY 75,396,700.92, up 141.06% from CNY 31,277,517.05 in Q1 2022[5] - Basic earnings per share for Q1 2023 were CNY 0.07, reflecting a 133.33% increase from CNY 0.03 in Q1 2022[5] - Total operating revenue for Q1 2023 reached ¥691,025,769.13, an increase of 25.1% compared to ¥552,693,027.82 in the same period last year[24] - Net profit for Q1 2023 was ¥88,250,623.91, significantly higher than ¥37,369,678.01 in Q1 2022, marking an increase of 136%[24] - The net profit attributable to the parent company for Q1 2023 was ¥86,023,255.31, a significant increase of 130.7% compared to ¥37,261,834.25 in the same period last year[26] - The total comprehensive income for Q1 2023 reached ¥89,861,967.18, up from ¥35,001,141.95 in Q1 2022, reflecting a growth of 156.5%[26] - The basic and diluted earnings per share for Q1 2023 were both ¥0.07, compared to ¥0.03 in Q1 2022, indicating a 133.3% increase[26] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 67,428,674.56, a decline of 215.68% compared to a net inflow of CNY 58,291,240.96 in the previous year[15] - Cash inflows from operating activities totaled ¥630,138,811.39, an increase from ¥581,681,774.88 in the previous year, representing an 8.3% growth[29] - The net cash flow from operating activities was negative at -¥67,428,674.56, contrasting with a positive net cash flow of ¥58,291,240.96 in the same period last year[29] - Cash flow from financing activities for Q1 2023 was CNY 422,211,794.20, a substantial increase of 435.23% compared to a net outflow of CNY 125,945,830.64 in the same period last year[15] - The company raised ¥503,080,000.00 through financing activities in Q1 2023, compared to only ¥88,000,000.00 in the same period last year, indicating a substantial increase of 471.5%[29] - The net cash flow from financing activities was positive at ¥422,211,794.20, a significant turnaround from a negative cash flow of -¥125,945,830.64 in Q1 2022[29] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 6,295,381,169.09, an increase of 7.10% from CNY 5,877,980,374.42 at the end of the previous year[5] - Current assets totaled ¥2,331,885,668.81, up from ¥1,927,072,477.67, indicating a rise of 21%[22] - The company's total liabilities increased to ¥2,258,053,259.87 from ¥1,931,511,616.76, reflecting a growth of 16.9%[22] - The total equity attributable to shareholders reached ¥4,033,721,243.87, up from ¥3,945,089,460.91, an increase of 2.2%[22] - The total amount of cash and cash equivalents decreased from 1,010,326,594.35 CNY at the beginning of the year to 688,531,150.99 CNY at the end of the period[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,952[17] - The largest shareholder, Wang Tianxiang, holds 24.00% of the shares, totaling 285,499,420 shares[17] - The company has a total of 214,124,565 shares under lock-up for the largest shareholder, Wang Tianxiang, due to executive lock-up restrictions[19] - The second-largest shareholder, Jiang Chen, holds 2.53% of the shares, totaling 30,062,100 shares[17] - The total number of restricted shares decreased from 223,588,823 to 221,835,508 during the reporting period[19] Expenses and Costs - Total operating costs for Q1 2023 were ¥613,468,747.82, up from ¥530,171,239.60, reflecting a rise of 15.7%[24] - The company reported a significant increase in financial expenses, which rose by 103.30% due to higher interest payments on bank loans[13] - Research and development expenses for Q1 2023 were ¥27,929,150.50, slightly higher than ¥26,813,029.82 in the previous year[24] Market and Future Outlook - The increase in revenue was primarily driven by higher sales volumes of certain products and an increased proportion of products won in national procurement, leading to a decrease in sales expenses as a percentage of revenue[9] - The company has no new product or technology developments mentioned in the reports[18] - There are no significant market expansion or acquisition strategies disclosed in the reports[18] - The company has not provided specific future outlook or performance guidance in the available documents[18] - The company reported a significant decrease in contract liabilities from ¥61,840,402.32 to ¥32,691,760.53, a reduction of 47.3%[22] - The company did not report any net profit from subsidiaries prior to consolidation in Q1 2023, consistent with the previous year[26]